Genomics BioSci & Tech Co (TPE:4195) Accounts Payable: NT$73.3 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:4195 Genomics BioSci & Tech Co Ltd TPE:4195
42 GF Score
Price NT$15.35
GF Value NT$34.15
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Genomics BioSci & Tech Co Accounts Payable?

Genomics BioSci & Tech Co TPE:4195 +0.33% 42 Accounts Payable is NT$73.3 Mil as of Mar. 2026. GuruFocus rates TPE:4195 with a GF Score™ of 42/100 and a GF Value™ of NT$34.15 (Possible Value Trap). The stock has 6 warning signs investors should review.

Genomics BioSci & Tech Co's Accounts Payable for the quarter that ended in Mar. 2026 was NT$73.3 Mil.

Genomics BioSci & Tech Co's quarterly Accounts Payable increased from Sep. 2025 (NT$112.7 Mil) to Dec. 2025 (NT$125.7 Mil) but then declined from Dec. 2025 (NT$125.7 Mil) to Mar. 2026 (NT$73.3 Mil).

Genomics BioSci & Tech Co's annual Accounts Payable increased from Dec. 2023 (NT$29.7 Mil) to Dec. 2024 (NT$94.4 Mil) and increased from Dec. 2024 (NT$94.4 Mil) to Dec. 2025 (NT$125.7 Mil).

Genomics BioSci & Tech Co Accounts Payable Related Terms

Genomics BioSci & Tech Co Accounts Payable Historical Data

* Premium members only.

The historical data trend for Genomics BioSci & Tech Co's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genomics BioSci & Tech Co Accounts Payable Chart

Genomics BioSci & Tech Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.31 40.47 29.73 94.37 125.67

Genomics BioSci & Tech Co Quarterly Data
Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 72.79 112.73 125.67 73.25
TPE:4195
42GF Score
Genomics BioSci & Tech Co Ltd TPE:4195
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genomics BioSci & Tech Co Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of NT$73.3 Mil mean?
Genomics BioSci & Tech Co (TPE:4195) has a Accounts Payable of NT$73.3 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Genomics BioSci & Tech Co and its competitors.
Is Genomics BioSci & Tech Co's Accounts Payable too high?
Genomics BioSci & Tech Co's current Accounts Payable is NT$73.3 Mil. Overall, Genomics BioSci & Tech Co has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Genomics BioSci & Tech Co's Accounts Payable compare to VRTX and REGN?
Genomics BioSci & Tech Co's Accounts Payable of NT$73.3 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Genomics BioSci & Tech Co and its competitors. Genomics BioSci & Tech Co's current Accounts Payable is NT$73.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomics BioSci & Tech Co stock overvalued right now?
Based on GuruFocus' analysis, Genomics BioSci & Tech Co (TPE:4195) is currently considered Possible Value Trap. The stock's GF Value™ is NT$34.15, compared to a current price of NT$15.35 — trading 55.1% below its estimated fair value. The current Accounts Payable is NT$73.3 Mil. Genomics BioSci & Tech Co's overall GF Score™ is 42/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Genomics BioSci & Tech Co (TPE:4195), the current Accounts Payable is NT$73.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genomics BioSci & Tech Co (TPE:4195) Overvalued in 2026?

Based on GuruFocus' analysis, Genomics BioSci & Tech Co stock appears to be undervalued. The current stock price of NT$15.35 is trading 55.1% below its estimated GF Value™ of NT$34.15. GuruFocus considers Genomics BioSci & Tech Co to be Possible Value Trap.

Key valuation signals for TPE:4195:

  • Accounts Payable: NT$73.3 Mil
  • GF Value™: NT$34.15 vs. price of NT$15.35 (55.1% below fair value)
  • GF Score™: 42/100 with 6 warning signs

No single metric tells the full story. See the TPE:4195 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genomics BioSci & Tech Co Business Description

Address 14th Floor, Number 100, Xintai 5th Road, Sec 1, Xizhi District, New Taipei City, Taipei, TWN
Genomics BioSci & Tech Co Ltd is a Taiwan based commercial genome sequencing company formed to develop medical genetic testing. The services of the company include Sanger sequence service, Synthesis Service and Genomic Service.
42GF Score

Get the complete analysis for TPE:4195

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$15.35
Price
NT$34.15
GF Value